Medication-related osteonecrosis of the jaw associated with bisphosphonates and denosumab in osteoporosis
Most of our cases were in the early stages of MRONJ, and the success rate after conservative treatment was high.
Role of Periostin in Adhesion and Migration of Bone Remodeling Cells
Role of Periostin in Adhesion and Migration of Bone Remodeling Cells
Bone-density tests
It’s worth getting a bone-density test if you’re older or have other risk factors for weak bones, because without it the first sign of osteoporosis is usually a broken bone. Autor: © 2011 American Medical … Leer más
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research
J Bone Miner Res. 2016 Jan;31(1):16-35. doi: 10.1002/jbmr.2708. Review. Hence, the Task Force suggests that after 5 years of oral BP or 3 years of intravenous BP, reassessment of risk should be considered. In women … Leer más
Contribution of Quadriceps Weakness to Fragility Fracture: A Prospective Study
J Bone Miner Res. 2016 Jan;31(1):208-14. doi: 10.1002/jbmr.2594. Epub 2015 Aug 4. These data indicate that muscle weakness is an independent determinant of fracture risk in men, but not in women. This sex difference suggests … Leer más
Epidemiology of fractures in type 2 diabetes
Bone. 2016 Jan;82:2-8. doi: 10.1016/j.bone.2015.05.032. Epub 2015 May 29. Review. This article is part of a Special Issue entitled «Bone and diabetes» Autor: Schwartz AV
Implications of exercise-induced adipo-myokines in bone metabolism
The beneficial effects of exercise on bone metabolism depends on the intermittent exposure to myokines which, instead, act as inflammatory/pro-resorptive mediators when chronically elevated; on the other hand, the reduction in the circulating levels of … Leer más
Oxidative stress, autophagy, epigenetic changes and regulation by miRNAs as potential therapeutic targets in osteoarthritis
A deeper knowledge of the mechanisms involved in chondrocyte aging could identify potential targets for the treatment of OA, a prevalent and therapeutic-orphan disease.
New PPARγ partial agonist improves obesity-induced metabolic alterations and atherosclerosis in LDLr-/- mice
GQ-177, a new thiazolidinedione, acts as a partial PPARγ agonist that improves obesity-associated insulin resistance and dyslipidemia with atheroprotective effects in LDLr-/- mice.
Efficacy and safety of alendronic acid in the treatment of osteoporosis in children
Alendronate increased bone mineral density and was well tolerated in all patients, therefore it could be considered as a therapeutic option in the treatment of osteoporosis in children.
